Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MDX-010: Phase I; Phase II for melanoma and prostate cancer

MEDX began an open-label, dose-escalation Phase I trial

Read the full 81 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE